Exelixis Announces Encouraging Results for Cabozantinib in Combination With Atezolizumab in Metastatic Castration-Resistant Prostate Cancer

Source :: Business Wire. February 10, 2020
Publication Year :: 2020
Abstract: Data from the COSMIC-021 trial will be presented on Thursday, February 13, 2020 at the American Society of Clinical Oncology's Genitourinary Cancers Symposium ALAMEDA, Calif. -- Exelixis, Inc. (NASDAQ:EXEL) today [...]

Subjects :: United States. Food and Drug Administration
Exelixis Inc. -- Company sales and earnings
Cabozantinib
Atezolizumab
Cobimetinib
Biotechnology industries -- Company sales and earnings
Sorafenib
Cancer metastasis
Professional associations
Company earnings/profit
Business
Business, international
Cabometyx (Medication)

Tools